Cargando…
CO50 Efficacy and Safety of Itolizumab for the Treatment of Coronavirus Disease (COVID-19): A Systematic Literature Review
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747500/ http://dx.doi.org/10.1016/j.jval.2022.09.129 |
| _version_ | 1784849614133788672 |
|---|---|
| author | Gurram, NS Vagicharla, RB Rayapureddy, G Kummari, P Pulleddula, K Mir, J Sharma, S Tanushree, C Kohli, IS Goyal, R Aggarwal, A Chakrawarthy, M |
| author_facet | Gurram, NS Vagicharla, RB Rayapureddy, G Kummari, P Pulleddula, K Mir, J Sharma, S Tanushree, C Kohli, IS Goyal, R Aggarwal, A Chakrawarthy, M |
| author_sort | Gurram, NS |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9747500 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97475002022-12-14 CO50 Efficacy and Safety of Itolizumab for the Treatment of Coronavirus Disease (COVID-19): A Systematic Literature Review Gurram, NS Vagicharla, RB Rayapureddy, G Kummari, P Pulleddula, K Mir, J Sharma, S Tanushree, C Kohli, IS Goyal, R Aggarwal, A Chakrawarthy, M Value Health Article Published by Elsevier Inc. 2022-12 2022-12-14 /pmc/articles/PMC9747500/ http://dx.doi.org/10.1016/j.jval.2022.09.129 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Gurram, NS Vagicharla, RB Rayapureddy, G Kummari, P Pulleddula, K Mir, J Sharma, S Tanushree, C Kohli, IS Goyal, R Aggarwal, A Chakrawarthy, M CO50 Efficacy and Safety of Itolizumab for the Treatment of Coronavirus Disease (COVID-19): A Systematic Literature Review |
| title | CO50 Efficacy and Safety of Itolizumab for the Treatment of Coronavirus Disease (COVID-19): A Systematic Literature Review |
| title_full | CO50 Efficacy and Safety of Itolizumab for the Treatment of Coronavirus Disease (COVID-19): A Systematic Literature Review |
| title_fullStr | CO50 Efficacy and Safety of Itolizumab for the Treatment of Coronavirus Disease (COVID-19): A Systematic Literature Review |
| title_full_unstemmed | CO50 Efficacy and Safety of Itolizumab for the Treatment of Coronavirus Disease (COVID-19): A Systematic Literature Review |
| title_short | CO50 Efficacy and Safety of Itolizumab for the Treatment of Coronavirus Disease (COVID-19): A Systematic Literature Review |
| title_sort | co50 efficacy and safety of itolizumab for the treatment of coronavirus disease (covid-19): a systematic literature review |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747500/ http://dx.doi.org/10.1016/j.jval.2022.09.129 |
| work_keys_str_mv | AT gurramns co50efficacyandsafetyofitolizumabforthetreatmentofcoronavirusdiseasecovid19asystematicliteraturereview AT vagicharlarb co50efficacyandsafetyofitolizumabforthetreatmentofcoronavirusdiseasecovid19asystematicliteraturereview AT rayapureddyg co50efficacyandsafetyofitolizumabforthetreatmentofcoronavirusdiseasecovid19asystematicliteraturereview AT kummarip co50efficacyandsafetyofitolizumabforthetreatmentofcoronavirusdiseasecovid19asystematicliteraturereview AT pulleddulak co50efficacyandsafetyofitolizumabforthetreatmentofcoronavirusdiseasecovid19asystematicliteraturereview AT mirj co50efficacyandsafetyofitolizumabforthetreatmentofcoronavirusdiseasecovid19asystematicliteraturereview AT sharmas co50efficacyandsafetyofitolizumabforthetreatmentofcoronavirusdiseasecovid19asystematicliteraturereview AT tanushreec co50efficacyandsafetyofitolizumabforthetreatmentofcoronavirusdiseasecovid19asystematicliteraturereview AT kohliis co50efficacyandsafetyofitolizumabforthetreatmentofcoronavirusdiseasecovid19asystematicliteraturereview AT goyalr co50efficacyandsafetyofitolizumabforthetreatmentofcoronavirusdiseasecovid19asystematicliteraturereview AT aggarwala co50efficacyandsafetyofitolizumabforthetreatmentofcoronavirusdiseasecovid19asystematicliteraturereview AT chakrawarthym co50efficacyandsafetyofitolizumabforthetreatmentofcoronavirusdiseasecovid19asystematicliteraturereview |